| Market Capitalization (Millions $) |
1,737 |
| Shares
Outstanding (Millions) |
177 |
| Employees |
3,072 |
| Revenues (TTM) (Millions $) |
842 |
| Net Income (TTM) (Millions $) |
-197 |
| Cash Flow (TTM) (Millions $) |
783 |
| Capital Exp. (TTM) (Millions $) |
203 |
Evotec Se
Evotec SE is a publicly-traded German biotechnology firm operating in the pharmaceutical and drug discovery industry. The company is headquartered in Hamburg, Germany, and has various locations and offices worldwide.
Evotec SE is primarily engaged in the development and discovery of drugs, which includes providing comprehensive solutions for the pharmaceutical industry. The company works with leading biopharmaceutical companies, academic institutions, and disease foundations, focusing on providing innovative solutions through collaborations and partnerships.
Founded in 1993, the company has over the years been focused on research and development, cutting-edge technologies and collaboration, drug discovery, and strategic partnerships. The company has built a reputation as a leading provider of high-value drug discovery services, particularly in the fields of neuroscience, oncology, and autoimmune diseases.
Their technology platform, called the "Evotec Operating System," integrates different lab technologies and data management capabilities, enabling high-throughput screening and drug identification. This platform has been instrumental in the company's success as it enables them to work collaboratively and efficiently in the drug discovery process.
Evotec SE's services range from target identification, validation, and optimization to drug screening, hit identification, and preclinical development. The company also offers customized solutions tailored for specific client needs and has several programs in clinical and pre-clinical stages of development.
Additionally, Evotec SE has an extensive drug development pipeline, which includes both proprietary programs as well as partnered programs. To date, the company has over 100 partners across the globe and an impressive portfolio of drug candidates.
In terms of financials, Evotec SE has been consistent in its revenue growth, with a revenue increase of 17% in 2020 compared to the previous year. As of mid-2021, the company reported a total of over 4,000 employees worldwide, showing significant growth and expansion over the years.
Overall, Evotec SE has established itself as a leading biotech company that leverages cutting-edge technologies, strategic partnerships, and collaboration in drug discovery and development. With a proven track record, a robust pipeline, and consistent growth, the company is well-positioned to continue making significant strides in the biotech industry.
Company Address: Essener Bogen 7 Hamburg 22419
Company Phone Number: 40 560810 Stock Exchange / Ticker: NASDAQ EVO
| EVO is expected to report next financial results on May 11, 2024. |
|
|
